Supplementary Figures – Indirect Treatment Comparisons of Avapritinib versus Midostaurin for Patients with Advanced Systemic Mastocytosis
|
Figure A: PRISMA flow diagram Figure B: Subgroup analyses for pooled EXPLORER and PATHFINDER – overall survival in the RAC-RE population Figure C: Subgroup analyses for pooled EXPLORER and PATHFINDER – overall response rate in the RAC-RE population Figure D: Subgroup analyses for pooled EXPLORER and PATHFINDER – complete remission rate in the RAC-RE population Figure E: Kaplan–Meier of pooled avapritinib (safety) versus pooled midostaurin (FAS) Figure F: Kaplan–Meier of PATHFINDER avapritinib (RAC-RE) versus pooled midostaurin (PEP) Figure G: Kaplan–Meier of pooled avapritinib (RAC-RE, midostaurin-naïve) versus pooled midostaurin (PEP) Figure H: Kaplan–Meier of pooled avapritinib (RAC-RE, 200 mg) versus pooled midostaurin (PEP) Figure I: Overall survival results when number of C-findings is included as a matching variable Figure J: Overall response rate and complete remission results when number of C-findings is included as a matching variable |
